Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients

Oncology Letters

Volumn 1, Issue 2, 2010, Pages 283-287

  Sasaki, Hidefumi ^a   Hikosaka, Yu ^a   Kawan, Osamu ^a   Moiyama, Satou ^a   Yan, Motoki ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

DLEC1 gene; Lung cancer; Methylation

Indexed keywords

PROTEIN; PROTEIN DLEC 1; PROTEIN P16; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; JAPAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; SMOKING;

EID: 77955723898     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000050     Document Type: Article

References (24)

1. Hung J, Kishimoto Y, Sugio K, et al: Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 273: 558-563, 1995.
2. Wistuba II, Behrens C, Virmani AK, et al: High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 60: 1949-1960, 2000.
3. Zaborovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21: 6915-6935, 2002.
4. Qiu GH, Salto-Tellez M, Ross JA, et al: The tumor suppressor gene DLEC 1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle. J Hepatol 48: 433-441, 2008.
5. Seng TJ, Currey N, Cooper WA, et al: DLEC 1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 99: 375-382, 2008.
6. Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E and Nakamura Y: Molecular cloning of a candidate tumor suppressor gene, DLC 1, from chromosome 3p.21.3. Cancer Res 59: 1966-1972, 1999.
7. Kwong J, Chow LS, Wong WK, et al: Epigenetic inactivation of deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma. Genes Chromosomes Cancer 46: 171-180, 2007.
8. Kwong J, Lee JY, Wong KK, et al: Candidate tumor-suppressor gene DLEC 1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8: 268-278, 2006.
9. Kang GH, Lee S, Cho NY, et al: DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest 88: 161-170, 2008.
10. Japan Lung Cancer Society: General Rule for Clinical and Pathological Record of Lung Cancer. 5th edition. Jpn Lung Cancer Soc 5: 1-177, 1999.
11. Paez JG, Janne PA, Lee JC, et al: EG FR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
12. Endo K, Konishi A, Sasaki H, et al: Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50: 375-384, 2005.
13. Sasaki H, Shimizu S, Endo K, et al: EG FR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 118: 180-184, 2006.
14. Sasaki H, Endo K, Konishi A, et al: EG FR mutation status in Japanese lung cancer patients: genotyping analysis using LighyCycler. Clin Cancer Res 11: 2924-2929, 2005.
15. Smith IM, Mithani SK, Liu C, et al: Novel integrative methods for gene discovery associated with head and neck squamous cell carcinoma development. Arch Otolaryngol Head Neck Surg 135: 487-495, 2009.
16. Nakata S, Sugio K, Uramoto H, et al: The methylation status and protein expression of CDH1, p16INK4A, and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 106: 2190-2199, 2006.
17. Ying J, Poon FF, Yu J, et al: DLEC 1 is a functional 3p22.3 tumor suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer 100: 663-669, 2009.
18. Jarmalaite S, Kannio A, Anttila S, et al: Aberrant p16 promoter methylation in smokers and former smokers with non-small cell lung cancer. Int J Cancer 106: 913-918, 2003.
19. Kim DH, Nelson HH, Wiencke JK, et al: P16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 61: 3419-3424, 2001.
20. Rom WN, Jay JG, Lee TC, Jiang Y and Tchou-Wong KM: Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med 161: 1355-1367, 2000.
21. Swafford DS, Middleton SK, Palmisano WA, et al: Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol Cell Biol 17: 1366-1374, 1997.
22. Kim DS, Kim MJ, Lee JY, et al: Aberrant methylation of E-cadherin and H-cadherin genes in non-small cell lung cancer and its relation to clinicopathologic features. Cancer 110: 2785-2792, 2007.
23. Ma BB, Sung F, Tao Q, et al: The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs. Jan, 27, 2009 (Epub ahead of print).
24. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I and Koeffler H P: Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 15: 2760-2770, 2004.